This episode currently has no reviews.
Submit ReviewShares of Walmart jumping on the back of a strong earnings report. What the retailer is saying about the state of the consumer, and why they see sales improving. Plus The Biden Administration unveiling drug prices subject to Medicare negotiations. The names being impacted, and how the pharma space will fare.
This episode currently has no reviews.
Submit ReviewThis episode could use a review! Have anything to say about it? Share your thoughts using the button below.
Submit Review